Aytu BioScience (AYTU) AI Stock Analysis

• Market Cap: $20.42M
• Dividend Yield: N/A
• Average Volume (3M): 185.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.77
• Revenue Growth: -18.05%
• EPS Growth: 33.87%
• Country: US
• Employees: 102
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.93
• Shares Outstanding: 9,911,913
• 10 Day Avg. Volume: 392,427
• 30 Day Avg. Volume: 185,570
• PEG Ratio: 0.04
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -6.32
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 0.10
• Enterprise Value/Gross Profit: 0.14
• Enterprise Value/Ebitda: 2.15
• 1Y Price Target: $7.25
• Price Target Upside: 316.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 50 Neutral
• Price Target: $2.00 ▲(14.94% Upside)

Aytu BioScience's overall score reflects significant financial challenges and valuation concerns, offset by strategic initiatives and positive earnings call sentiment. The upcoming ExuA launch and positive EBITDA are promising, but financial and technical weaknesses weigh heavily.

Positive Factors

ExuA Launch

The launch of ExuA, targeting a $22 billion U.S. market, could significantly enhance Aytu's market position, addressing unmet needs in MDD treatment.

Positive Adjusted EBITDA

Consistent positive adjusted EBITDA indicates operational efficiency and financial health, supporting sustainable business growth.

Pediatric Portfolio Growth

Growth in the pediatric portfolio demonstrates successful execution of the company's return to growth plan, enhancing revenue diversification.

Negative Factors

Decline in Gross Margin

A decline in gross margin reflects increased production costs, potentially impacting profitability and requiring cost management strategies.

ADHD Portfolio Stability Concerns

Flat revenue and potential generic competition in the ADHD portfolio could threaten market share and revenue stability.

Impairment Expense Impact

The impairment expense indicates a strategic shift and potential financial strain, impacting short-term financial results and resource allocation.

Aytu BioScience Business Overview & Revenue Model

Company Description

Aytu BioScience, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative products in the field of urology, pediatrics, and other therapeutic areas. The company primarily aims to address unmet medical needs through its proprietary products and partnerships, offering solutions that improve patient care and outcomes. Aytu's core products include various prescription medications and diagnostic tools designed to enhance the treatment of conditions such as testosterone deficiency and other urological disorders.

How the Company Makes Money

Aytu BioScience generates revenue through the sale of its pharmaceutical products and diagnostic tests. The company has a diversified revenue model that includes direct sales of its proprietary products, as well as partnerships with other pharmaceutical companies for co-promotion and distribution. Key revenue streams are derived from product sales in the urology and pediatric markets, where Aytu has established a presence. Additionally, the company may benefit from licensing agreements, collaborations, and research grants that contribute to its financial performance. Strategic partnerships with healthcare providers and institutions also play a crucial role in expanding its market reach and enhancing sales.

Aytu BioScience Financial Statement Overview

Summary

Aytu BioScience faces significant financial challenges, with declining revenues and persistent losses impacting profitability. While the company maintains a manageable debt level, its negative return on equity and cash flow issues highlight the need for strategic improvements to enhance financial stability and growth prospects.

Income Statement

Aytu BioScience's income statement reveals challenges with profitability and revenue growth. The company has experienced a decline in revenue over the past year, with a negative revenue growth rate of -4.10%. Gross profit margin remains relatively strong at 69.04%, indicating efficient production, but the net profit margin is negative at -20.43%, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.10, suggesting manageable leverage. However, the return on equity is significantly negative at -71.51%, indicating poor returns for shareholders. The equity ratio stands at 15.27%, showing a reasonable proportion of equity financing relative to total assets.

Cash Flow

Cash flow analysis indicates a concerning decline in free cash flow growth at -62.28%. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. However, the free cash flow to net income ratio is positive at 1.12, suggesting that free cash flow covers net losses, albeit with limited margin.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	69.22M	66.38M	81.00M	107.40M	96.67M	65.63M
Gross Profit	47.48M	45.83M	49.37M	66.63M	46.44M	29.20M
EBITDA	3.16M	-7.83M	-1.01M	-3.27M	-98.74M	-29.04M
Net Income	1.64M	-13.56M	-15.84M	-17.05M	-108.78M	-58.29M
Balance Sheet
Total Assets	124.20M	124.18M	118.09M	136.46M	137.62M	265.67M
Cash, Cash Equivalents and Short-Term Investments	18.17M	30.95M	20.01M	22.98M	19.36M	49.65M
Total Debt	1.86M	1.86M	16.42M	18.45M	18.19M	28.35M
Total Liabilities	89.30M	105.21M	90.38M	97.11M	93.31M	128.10M
Stockholders Equity	34.90M	18.97M	27.72M	39.36M	44.31M	137.57M
Cash Flow
Free Cash Flow	-5.74M	-2.17M	-1.39M	-5.13M	-28.82M	-28.30M
Operating Cash Flow	-5.53M	-1.94M	-1.39M	-5.13M	-28.82M	-25.96M
Investing Cash Flow	423.00K	-2.56M	-329.00K	-117.00K	-3.25M	-2.78M
Financing Cash Flow	3.52M	15.44M	-1.26M	8.87M	1.53M	30.31M

Aytu BioScience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.74
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Negative. The current price of 1.74 is below the 20-day moving average (MA) of 2.28, below the 50-day MA of 2.34, and below the 200-day MA of 1.76, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 26.02 is Positive, neither overbought nor oversold. The STOCH value of 5.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AYTU.

Aytu BioScience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COSM	53 Neutral	33.49M	-1.09	-65.96%	―	―	―
AYTU	50 Neutral	$20.42M	―	-60.76%	―	-18.05%	33.87%
TXMD	47 Neutral	12.38M	-26.82	―	―	156.93%	92.75%
FLGC	44 Neutral	12.28M	-0.61	-352.71%	―	-24.10%	38.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Aytu BioScience Corporate Events

Aytu BioScience Expands Lending Agreement for EXXUA Launch

On June 20, 2025, Aytu BioPharma, Inc. expanded and extended its lending agreement with Eclipse Business Capital LLC to provide added working capital flexibility in anticipation of the commercial launch of EXXUA™ in late 2025. This agreement includes extending the term loan maturity to June 2029, increasing the principal balance to $13.0 million, and expanding the revolving credit facility by $1.5 million. EXXUA, a novel antidepressant, is expected to enter the over $22 billion U.S. prescription MDD market, addressing significant unmet needs due to its favorable side effect profile demonstrated in clinical trials.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioPharma Closes $16.6M Stock Offering for EXXUA

On June 9, 2025, Aytu BioPharma announced the closing of an upsized at-the-market public offering of common stock, raising gross proceeds of $16.6 million. The funds are intended to support the commercialization of EXXUA™, a novel FDA-approved treatment for major depressive disorder, which is expected to launch in the fourth quarter of 2025. This strategic move positions Aytu to enter the $22 billion U.S. prescription MDD market, with EXXUA expected to be a significant growth driver due to its unique mechanism and favorable side effect profile.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioScience Signs Exclusive Agreement for EXXUA

On June 5, 2025, Aytu BioPharma entered an Exclusive Commercialization Agreement with Fabre-Kramer Holdings to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, an FDA-approved treatment for major depressive disorder (MDD), is expected to launch in the fourth quarter of 2025. The agreement involves a series of financial commitments, including upfront and milestone payments, royalties, and a supply price based on net sales. EXXUA is anticipated to be a significant growth catalyst for Aytu, addressing unmet needs in the $22 billion US prescription MDD market. The product is distinguished by its novel mechanism and lack of sexual dysfunction side effects, positioning it as a transformative option for over 21 million Americans affected by MDD.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioPharma Announces $12.9M Public Offering

On June 5, 2025, Aytu BioPharma announced an underwriting agreement with Lake Street Capital Markets for a public offering of common stock and prefunded warrants, aiming to raise approximately $12.9 million. The proceeds will be used for general corporate purposes and to commercialize EXXUA™ (gepirone) extended-release tablets. The offering, expected to close around June 9, 2025, is part of Aytu’s strategy to strengthen its market position in novel therapeutics for major depressive disorder.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioScience Holds 2025 Annual Meeting

On May 21, 2025, Aytu BioScience held its 2025 Annual Meeting, where approximately 70% of the company’s common stockholders participated. During the meeting, all incumbent directors were reelected, an amendment to increase shares under the 2023 Equity Incentive Plan was approved, Grant Thornton LLP was ratified as the independent accounting firm, and executive compensation was endorsed through a non-binding advisory vote.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.